BIIB Biogen Inc.

219.71
+3  (+1%)
Previous Close 216.71
Open 220.02
Price To Book 3.31
Market Cap 43217903389
Shares 196,708,784
Volume 4,212,320
Short Ratio
Av. Daily Volume 1,770,400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial initiated 4Q 2017.
BIIB054
Parkinson's disease
Phase 2 trial initiated October 2017.
Natalizumab - OPUS
Epilepsy
Phase 3 commencement of enrollment announced September 4, 2018.
BIIB093
Large hemispheric infarction
Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 data due 2H 2019.
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 2 planned.
BIIB092 - Anti Tau
Alzheimer’s disease
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 trial to be initiated later in 2019.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b data due mid-2020.
Opicinumab (AFFINITY)
Multiple sclerosis (MS)
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b data released February 8, 2018 - primary endpoint not met.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 data released September 2018 - primary endpoint not met.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 dosing commenced October 2016.
BIIB059 (anti-BDCA2)
Lupus
Phase 2b data released October 23, 2018 - primary endpoint not met.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 3 initiation announced March 22. 2019.
BAN2401
Alzheimer’s disease
Phase 2b trial initiated September 2018.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data released June 8, 2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 1/2 data due 2019.
IONIS-SOD1Rx
Amyotrophic lateral sclerosis (ALS)
Phase 3b trial initiation announced January 3, 2019.
Natalizumab - NOVA
Multiple sclerosis (MS)
Phase 2b trial initiated December 2018.
BIIB104
Cognitive Impairment Associated With Schizophrenia (CIAS)

Latest News

  1. Dow Turns Lower as Slowing Global Growth Worries Weigh on Wall Street
  2. Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group
  3. Biogen Stock Likely Won’t See a Boost From Buybacks, Analysts Say
  4. Biogen announces $5 billion buyback days after shelving Alzheimer's trials
  5. Biogen Announces $5 Billion Buyback Just Days After Stock Plunge
  6. Avon and Biogen Gain, and 3 Other Stocks Making Moves
  7. 5 biotech stocks that could be the next big winners
  8. Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge
  9. Biogen stock plummets 28% after company halts Alzheimer’s trials
  10. Stocks - Viacom Jumps in Premarket, Nike, Apple Drop, Boeing Gains
  11. Is It Safe to Buy Biogen Stock Right Now?
  12. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
  13. 2 Biotech Takeout Targets Perfect for Biogen
  14. Primecap's Biogen Exposure Could Be History Repeating
  15. Biogen Skids On Alzheimer's Flop — And Unveils Yet Another Study
  16. Current Stock Market Reverses Lower But Apple, Amazon Strong; Boeing 737 Max Probe; Biogen Dives: Weekly Review
  17. Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
  18. Biogen Stock Is Falling Again Because Even a Massive Plunge Doesn’t Make it a Bargain Buy
  19. Biogen Stock Crashes on Termination of Alzheimer's Studies